Sensei Biotherapeutics’ (FTH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. Oppenheimer started coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Leerink Partners started coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $54.90.

Sensei Biotherapeutics Price Performance

FTH opened at $28.55 on Tuesday. The stock has a market capitalization of $737.73 million, a P/E ratio of -0.20 and a beta of -0.25. The stock has a 50-day simple moving average of $26.52. Sensei Biotherapeutics has a twelve month low of $7.21 and a twelve month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter. On average, research analysts expect that Sensei Biotherapeutics will post -13.18 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Anand Kiran Parikh purchased 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer directly owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder James Peyer sold 25,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider owned 130,142 shares of the company’s stock, valued at $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have bought 49,494 shares of company stock valued at $1,188,822. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in Sensei Biotherapeutics during the first quarter valued at $22,758,000. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.